MAPS to Investigate Viability of Research Pathway for MDMA-Assisted Therapy to Treat Traumatic Brain Injury Effort Positions MAPS, Sponsor of the Only Completed Phase 3 Trial for Psychedelic-Assisted Therapy, to Serve New Unique Role Within CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), an emerging data-driven life…


Previous articlePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
Next articlePT262 – Carlene MacMillan, M.D. – Set, Setting, and Systems: Adding Insurance to the Conversation